Floatz logo

ERIBULIN MONOMETHANESULFONATE

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

121 Active assets in the Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

ERIBULIN MONOMETHANESULFONATE is also rated in:

breast neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
69 / 100
View asset →
Metastatic Triple-Negative Breast CarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →